Open AccessProgress and Development in Treatment of Covid – 19, and Vaccine development: A Review
Author(s) -
Vijay Prakash Sonar,
Vijayendra S. Dalvi,
Shailesh S. Chalikwar
Publication year - 2021
Publication title -
american journal of pharmtech research
Language(s) - English
Resource type - Journals
ISSN - 2249-3387
DOI - 10.46624/ajptr.2021.v11.i4.005
Subject(s) - nitazoxanide , covid-19 , pandemic , medicine , lopinavir , hydroxychloroquine , ritonavir , pneumonia , intensive care medicine , virology , immunology , human immunodeficiency virus (hiv) , outbreak , viral load , antiretroviral therapy , infectious disease (medical specialty) , disease
The entire world is facing a worst situation of pandemic ever. It’s been more than 18 months after the initial reports on Covid from China, and the pandemic is still going. As per the data available over the WHO website as of 23 June 2021, there have been 178,837,204 confirmed cases of COVID-19, including 3,880,450 deaths, reported to WHO. As of 21 June 2021, a total of 2,414,347,324 vaccine doses have been administered. Despite of having more than 15 vaccines for Covid-19; the challenge to treat a patient with a define line of treatment remains the same. In the present review we have made an attempt to summarize the various medicines which are being used by medical practitioner in India and overseas. Use of different drug molecules like Remdesivir, Tocilzumab, Hydroxychloroquine, Azithromycine, Ivermectin, Steroids, Doxicycline, Ecosprine, Low molecular weight Heparin, Lopinavir and Ritonavir, Nitazoxanide, Baricitinib etc. were highlighted; although the list is long. A focus is made on the different types of vaccines available till date and their status in various countries. Keywords: Covid-19, Vaccine, Antiviral, Pandemic, Antibiotics.